RESUMEN
BACKGROUND AND OBJECTIVES: Passive immunization by the infusion of convalescent plasma (CP) obtained from patients who have recently recovered from COVID-19, thus having antibodies to severe acute respiratory syndrome coronavirus 2, is a potential strategy to reduce the severity of illness. A high prevalence of antiphospholipid antibodies (APLA) in patients with COVID-19 has been reported during the pandemic, raising a concern whether the use of CP could increase the risk of thrombosis in transfused patients. We aimed to evaluate the prevalence of APLA in COVID-19 CP (CCP) in order to assess the potential prothrombotic influence of transfused CCP to COVID-19 patients. MATERIALS AND METHODS: We studied the prevalence of APLA in 122 CCP samples collected from healthy donors who recovered from mild-COVID-19 at two time periods: September 2020-January 2021 (defined as 'early period' samples) and April-May 2021 (defined as 'late period' samples). Thirty-four healthy subjects unexposed to COVID-19 were used as controls. RESULTS: APLA were present in 7 of 122 (6%) CCP samples. One donor had anti-ß2-glycoprotein 1(anti-ß2GP1) IgG, one had anti-ß2GP1 IgM and five had lupus anticoagulant (LAC) using silica clotting time (SCT), all in 'late period' donors. In the control group, one subject had anti-ß2GP1 IgG, two had LAC using dilute Russell viper venom time (dRVVT) and four had LAC SCT (both LAC SCT and LAC dRVVT in one subject). CONCLUSION: The low prevalence of APLA in CCP donors reassures the safety of CCP administration to patients with severe COVID-19.
Asunto(s)
Síndrome Antifosfolípido , COVID-19 , Humanos , COVID-19/epidemiología , COVID-19/terapia , Sueroterapia para COVID-19 , Anticuerpos Antifosfolípidos , Inhibidor de Coagulación del Lupus , Inmunoglobulina G , Inmunización Pasiva , Anticuerpos AntiviralesRESUMEN
BACKGROUND: In December 2020 the Israeli Health Ministry began a mass vaccination campaign with the BNT162b2 vaccine. This was an important step in overcoming the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) pandemic. Autoimmune phenomenon have been described after receiving vaccinations. PATIENTS/METHODS: Here we describe a case series of patients who developed acquired Thrombotic Thrombocytopenic Purpura, a rare autoimmune disease, within several days of receiving the BNT162b2 vaccine. CONCLUSIONS: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity should be evaluated in patients with history of aTTP before and after any vaccination, especially the SARS-CoV-2 vaccination, and immunosuppression treatment should be considered before vaccination in cases of low ADAMTS13 activity. Patients should be closely monitored after the vaccine for clinical situation and laboratory data. Post vaccination thrombocytopenia assessment should include immune thrombocytopenic purpura, vaccine-induced immune thrombotic thrombocytopenia and acquired thrombotic thrombocytopenic purpura.
Asunto(s)
COVID-19 , Púrpura Trombocitopénica Idiopática , Púrpura Trombocitopénica Trombótica , Proteína ADAMTS13 , Vacuna BNT162 , Vacunas contra la COVID-19 , Humanos , Púrpura Trombocitopénica Idiopática/inducido químicamente , Púrpura Trombocitopénica Idiopática/diagnóstico , Púrpura Trombocitopénica Trombótica/inducido químicamente , Púrpura Trombocitopénica Trombótica/diagnóstico , Enfermedades Raras , SARS-CoV-2RESUMEN
To investigate if patients treated with oral anticoagulants (OAC) have delayed surgical intervention (more than 48 h) compared to patients without OAC therapy, and if there is an impact to surgery timing on hospitalization length and mortality. A retrospective cohort study of all patients aged over 65 registered with a new diagnosis of hip fracture who underwent surgery in one of the general hospitals run by Clalit, Israel between 01/01/2014 and 31/12/2017. Data was retrieved for patient demographics, OAC treatment, and Charlson comorbidity index. 5828 patients were operated for hip fractures, mean age was 82.8 years (65-108), 4013 (68.8%) were female. 415 were treated with direct oral anticoagulants (DOACs) (7.1%) and 311 with warfarin (5.3%) prior to their hospitalization. Patients taking OAC were less likely to be operated within 48 h from arrival to the hospital compared to patients not receiving OAC. The 30 day mortality was 4.2% among patients not receiving OAC, 6.0% among patients taking DOACs and 10.0% among patients receiving warfarin (p < 0.001). Adjusted odds ratio for mortality at 30 day among patients taking DOACs was similar to patients who didn't take OAC. (OR 1.0, CI 0.7, 1.6). The 30 day mortality rate of patients who were receiving OAC (either DOACs or warfarin) was not significantly different whether patients were operated within 48 h or not. Mortality rate was highest among patients taking warfarin. For patients who received DOACs, operation within 48 h wasn't associated with lower mortality rate. In these patients it seemed reasonable to adjust surgery time according to patients' characteristics and needs.
Asunto(s)
Fracturas de Cadera , Warfarina , Administración Oral , Anciano , Anciano de 80 o más Años , Anticoagulantes/uso terapéutico , Femenino , Fracturas de Cadera/tratamiento farmacológico , Fracturas de Cadera/cirugía , Humanos , Estudios Retrospectivos , Warfarina/uso terapéuticoRESUMEN
: Evaluation of bleeding risk before operation includes history of bleeding, complete blood count and basic coagulation tests, prothrombin time and activated partial thromboplatin time (aPTT). In this article, we present a patient with colon cancer who presented with asymptomatic prolonged aPTT of 72-100âs, while past a PTT values were within normal limits. aPTT was corrected in vitro by mixing with normal plasma. Further laboratory workup excluded coagulation factors deficiencies or an acquired inhibitor to coagulation factors. The patient underwent uncomplicated laparoscopic anterior resection of a recto-sigmoid carcinoma after receiving fresh frozen plasma and correction of aPTT. Further investigation revealed a rare disorder of an acquired prekallikrein deficiency. We describe the patient's clinical presentation, laboratory workup and review the literature of contact phase proteins deficiency.
Asunto(s)
Tiempo de Tromboplastina Parcial/efectos adversos , Anciano , Humanos , MasculinoRESUMEN
INTRODUCTION: Primary immune thrombocytopenic purpura (ITP) is an acquired immune-mediated disorder characterized by isolated thrombocytopenia (platelet count less than 100X109/L), caused by IgG autoantibodies which bind to platelets and megakaryocyte, T cell-mediated platelet destruction and impaired megakaryocytic function. Symptoms can manifest as petechiae, purpura, mucosal bleeding and rarely fatal intracranial hemorrhage, as well as reduced quality of life. A wide range of bleeding manifestations exists and it is impossible to tell who will bleed, when and where. The goal of treatment is to prevent severe/life-threatening bleeding. Treatment modalities target various aspects of ITP pathophysiology such as the inhibition of autoantibody production (decreased autoimmune process), modulation of T cell activity (with prolongation of platelets survival), and stimulation of platelet production. The American Society of Hematology and the International Society of Thrombosis and Hemostasis published guidelines on the treatment of ITP patients, where first line treatment focuses on inhibition of autoantibody production and platelet degradation, second-line treatments include immunosuppressive drugs and splenectomy, and third-line treatments aim to stimulate platelet production by megakaryocytes. New available strategies might change the order of treatment lines. As in other situations, treatment should be tailored according to the patient's age, life style, comorbidities and compliance.
Asunto(s)
Púrpura Trombocitopénica Idiopática , Adulto , Plaquetas , Humanos , Megacariocitos , Púrpura Trombocitopénica Idiopática/complicaciones , Púrpura Trombocitopénica Idiopática/terapia , Calidad de Vida , TrombopoyesisRESUMEN
OBJECTIVE: To assess outcomes after 20 weeks of pregnancy according to autoantibody profile and clinical presentation of maternal antiphospholipid syndrome (APS). METHODS: The present retrospective cohort analysis included women diagnosed with APS at a tertiary medical center in Israel between January 1, 2012, and December 31, 2016. Anticardiolipin antibodies, anti-ß2-glycoprotein antibodies, and lupus anticoagulant were assessed. Participants were stratified by type of APS (obstetric vs thrombotic), antibody profile, and antibody titer (low vs high). Primary composite outcomes were rated as severe (stillbirth, fetal growth restriction at <34 weeks, severe pre-eclampsia, or delivery at <32 weeks) and mild (stillbirth, any fetal growth restriction, any pre-eclampsia, or delivery at <34 weeks). RESULTS: A total of 99 women were included in the analysis. The primary composite outcomes were similar regardless of stratification. Lupus anticoagulant positivity was associated with delivery before 37 weeks. When compared with low antibody titer, high antibody titer was associated delivery at or before 32 weeks (P=0.045) and 34 weeks (P=0.029). CONCLUSION: High antibody titer might be associated with an increased risk of severe prematurity among pregnant women with APS.
Asunto(s)
Síndrome Antifosfolípido/inmunología , Retardo del Crecimiento Fetal/inmunología , Preeclampsia/inmunología , Complicaciones del Embarazo/inmunología , Nacimiento Prematuro/inmunología , Adulto , Anticuerpos Anticardiolipina/sangre , Anticuerpos Anticardiolipina/inmunología , Síndrome Antifosfolípido/sangre , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Femenino , Humanos , Recién Nacido de Bajo Peso/inmunología , Israel , Inhibidor de Coagulación del Lupus/sangre , Inhibidor de Coagulación del Lupus/inmunología , Embarazo , Complicaciones del Embarazo/sangre , Resultado del Embarazo , Glicoproteínas beta 1 Específicas del Embarazo/análisis , Glicoproteínas beta 1 Específicas del Embarazo/inmunología , Estudios Retrospectivos , Mortinato , Adulto JovenRESUMEN
INTRODUCTION: Antithrombotic and antiplatelet therapy is widely used for primary and secondary prevention of venous and arterial diseases. Hemorrhage is a frequent complication in patients taking these drugs, especially during and post invasive procedures. There are several oral anticoagulants and antiplatelet drugs that differ from each other in the mechanism of action and metabolism, the need for drug monitoring, antidote, and the peri-procedural management of the drug. The risk of bleeding in gastrointestinal endoscopic procedures can be high (≥ 1.5%), depending on the procedure. Patients taking antithrombotic and antiplatelet therapy should undergo evaluation before endoscopic procedure in order to stratify their risk for bleeding during the procedure on the one hand, and the risk of thromboembolism- if the drug is interrupted, on the other hand. This review provides general recommendations and approaches for patients undergoing elective gastrointestinal endoscopic procedures while receiving antithrombotic or antiplatelet drugs.
Asunto(s)
Anticoagulantes/administración & dosificación , Endoscopía , Hemorragia/prevención & control , Inhibidores de Agregación Plaquetaria/administración & dosificación , Tromboembolia/prevención & control , HumanosRESUMEN
BACKGROUND: A 75 year old patient presenting with mucocutaneous bleeding was diagnosed with acquired thrombasthenia. The diagnosis was based on lack of platelet aggregation with adenosine diphosphate (ADP), arachidonic acid and collagen, and normal aggregation induced by ristocetin. OBJECTIVE: To study the mechanism of platelet function inhibition in a patient with acquired thrombasthenia. METHODS: Aggregation assays of platelets from the patient and healthy controls were performed. In addition, anti-glycoprotein (GP) IIbIIIa antibodies bindingto normal in the presence or absence of the patient's serum was by flow cytometry. RESULTS: Aggregation of normal platelets in the presence of patient's plasma was inhibited four- and 2.5-fold in the presence of ADP and arachidonic acid respectively, while collagen-induced aggregation was completely abolished. Ristocetin-induced aggregation was normal. The patient's serum inhibited binding of commercial anti-glycoprotein IIbIIIa antibodies to normal platelets twofold by flow cytometry. Treatment with anti-CD20 monoclonal antibody (rituximab) normalized the patient's platelet aggregation. CONCLUSIONS: These results suggest that the patient developed inhibitory anti-GPIIbIIIa autoantibodies that caused acquired thrombasthenia.
Asunto(s)
Autoanticuerpos/análisis , Trastornos de las Plaquetas Sanguíneas , Agregación Plaquetaria , Pruebas de Función Plaquetaria/métodos , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/inmunología , Adenosina Difosfato , Anciano , Anticuerpos Monoclonales de Origen Murino/administración & dosificación , Ácido Araquidónico , Trastornos de las Plaquetas Sanguíneas/diagnóstico , Trastornos de las Plaquetas Sanguíneas/etiología , Trastornos de las Plaquetas Sanguíneas/inmunología , Colágeno , Monitoreo de Drogas/métodos , Femenino , Humanos , Factores Inmunológicos/administración & dosificación , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/inmunología , Agregación Plaquetaria/efectos de los fármacos , Agregación Plaquetaria/inmunología , Inducción de Remisión , Ristocetina , Rituximab , Resultado del TratamientoRESUMEN
BACKGROUND: Anti-complement factor H (CFH) antibodies is an extremely rare cause of atypical hemolytic uremic syndrome (aHUS) in adults, with less than 10 cases reported thus far. Although infectious diarrhea is a common inciting trigger for aHUS episode, there are no reports of an association with inflammatory bowel disease. Eculizumab is an emerging treatment for aHUS. Eculizumab has not been reported thus far to be given for aHUS due to anti-CFH antibodies. We report here for the first time on an adult patient with ulcerative colitis (UC) who developed aHUS due to anti-CFH antibodies, presented with decreased serum levels of both C3 and C4. She had an excellent response to treatment with eculizumab. CASE PRESENTATION: A 27-year-old Caucasian woman, who suffered from steroid-dependent UC, was admitted with microangiopathic hemolytic anemia and acute kidney injury with nephrotic syndrome. ADAMTS 13 was normal and comprehensive workout for secondary causes of HUS was negative. Both serum complement level of C3 and C4 were low. Kidney biopsy was compatible with the diagnosis of HUS with negative immunofluorescence. Because of only partial response to plasma exchange and high dose steroids, eculizumab was commenced. After two weeks signs of microangiopathy subsided, and kidney function began to recover. Few months after the diagnosis, a complement components investigation revealed antibodies against CFH at high titer of 2000 arbitrary units. Today her creatinine is stable with no proteinuria and no signs of HUS.
Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Síndrome Hemolítico Urémico Atípico/tratamiento farmacológico , Adulto , Síndrome Hemolítico Urémico Atípico/inmunología , Factor H de Complemento/inmunología , Femenino , HumanosAsunto(s)
Anticoagulantes/uso terapéutico , Síndrome Antifosfolípido/tratamiento farmacológico , Trasplante de Riñón/métodos , Fragmentos de Péptidos/uso terapéutico , Adulto , Anticoagulantes/efectos adversos , Antitrombinas/efectos adversos , Antitrombinas/uso terapéutico , Enfermedad Catastrófica , Femenino , Heparina/efectos adversos , Heparina/uso terapéutico , Hirudinas/efectos adversos , Humanos , Fragmentos de Péptidos/efectos adversos , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/uso terapéutico , Trombocitopenia/inducido químicamenteRESUMEN
UNLABELLED: Vena cava filters (VCFs) are used to prevent pulmonary embolism when anticoagulation is contraindicated or in the event of progression of thrombosis despite adequate anticoagulation. Retrievable VCFs provide a potential advantage over permanent VCFs, but the appropriateness of their use and the frequency with which they are removed is not well established. OBJECTIVES: Document the indications for insertion of retrievable VCFs, filter removal in hospital practice. METHODS: Observational study conducted in three academic medical centers. Consecutive patients undergoing retrievable VCF insertion were identified. Clinical data was extracted from the patients' charts and follow up data were obtained from treating physicians after discharge. RESULTS: 300 patients were studied. The indication for filter insertion was acute bleeding (46.1%) or surgery (24.2%) in patients with acute thrombosis, prevention of venous thromboembolism in trauma (13.3%), potential bleeding in patients with deep vein thrombosis (9.1%) thromboembolism while on adequate anticoagulation (5.7%) and other (1.3%). 21 (7%) filters were removed. An unsuccessful attempt at retrieval was undertaken in a further 9 (3%) patients. CONCLUSIONS: The use of retrievable VCFs was appropriate, with the possible exception of their prophylactic use in major trauma. The majority of VCFs were not removed, for reasons that are not apparent.
Asunto(s)
Remoción de Dispositivos/estadística & datos numéricos , Hemorragia/terapia , Filtros de Vena Cava/estadística & datos numéricos , Tromboembolia Venosa/terapia , Heridas y Lesiones/terapia , Centros Médicos Académicos/estadística & datos numéricos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Hemorragia/mortalidad , Humanos , Israel/epidemiología , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Práctica Profesional/estadística & datos numéricos , Estudios Retrospectivos , Tromboembolia Venosa/mortalidad , Heridas y Lesiones/mortalidad , Adulto JovenRESUMEN
Acquired thrombotic thrombocytopenic purpura (TTP) is an uncommon disease in adults, characterized by fever, neurological manifestations, microangiopathic hemolytic anemia, thrombocytopenia, renal dysfunction, and the presence of antibodies against the enzyme ADAMTS13. Treatment with plasmapheresis has increased the survival from 10% to more than 90%. Still, there is a subset of patients with resistant TTP who fail to respond to plasmapheresis or remain dependent on this procedure. There is mounting evidence that rituximab may play an important role in remission induction of resistant/relapsing TTP, but the extent of the remission is unknown. We present here four patients with chronic-relapsing TTP who responded favorably to rituximab. All four patients achieved prolonged remission of 23 to 82 months after the treatment. One patient relapsed 6 years afterthe initial treatment with rituximab and re-entered remission following retreatment.
Asunto(s)
Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Factores Inmunológicos/uso terapéutico , Adulto , Antígenos CD20 , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Púrpura Trombocitopénica Trombótica/tratamiento farmacológico , Recurrencia , Inducción de Remisión , Estudios Retrospectivos , Rituximab , Factores de Tiempo , Adulto JovenRESUMEN
PURPOSE OF REVIEW: To describe current knowledge related to the association between oral contraception and the thrombophilias. RECENT FINDINGS: The use of oral contraception increases the risk of venous thromboembolism as well as arterial thrombosis. Third-generation pills seem to increase the risk of venous thromboembolism compared with second-generation pills. This effect seems to be reversed or absent for the risk of arterial thrombosis. The effect of oral contraception on the risk of venous thromboembolism is more pronounced during the first year of use. All these risks are further increased in patients with an inborn or acquired tendency for coagulation (thrombophilia). SUMMARY: Prospective users of oral contraception are potential candidates for screening/testing, because a positive screen may substantially decrease the risk of a thrombotic event. At present, the available testing methods are not cost effective, and the absolute risk is not defined for each thrombophilia. Until these shortcomings are solved, it is not recommended to test every woman who wishes to use oral contraception. Nevertheless, before starting on oral contraception, each patient should be carefully screened by a physician who should identify an increased risk of thrombophilia and tailor the laboratory testing.
Asunto(s)
Anticonceptivos Hormonales Orales/efectos adversos , Trombofilia/complicaciones , Trombofilia/diagnóstico , Trombosis/inducido químicamente , Pruebas de Coagulación Sanguínea/economía , Pruebas de Coagulación Sanguínea/métodos , Anticonceptivos Hormonales Orales/administración & dosificación , Anticonceptivos Sintéticos Orales/administración & dosificación , Anticonceptivos Sintéticos Orales/efectos adversos , Análisis Costo-Beneficio , Femenino , Humanos , Tamizaje Masivo/economía , Tamizaje Masivo/métodos , Medición de Riesgo , Factores de RiesgoRESUMEN
Thrombophilia screening may be useful in patients at high risk of VTE because it may improve clinical outcome. Family screening allows primary prophylaxis for high-risk situations and counseling of women considering hormonal therapy and pregnancy. Until we find useful and inexpensive screening tools, it is not recommended to test every patient or her/his relatives. Each index case should be carefully evaluated by an expert physician who should tailor the laboratory testing and treatment modalities.
Asunto(s)
Tamizaje Masivo , Trombofilia/diagnóstico , Factores de Edad , Análisis Costo-Beneficio , Femenino , Humanos , Tamizaje Masivo/economía , Tamizaje Masivo/métodos , Persona de Mediana Edad , Embarazo , Complicaciones Hematológicas del Embarazo , Trombofilia/genéticaRESUMEN
The latest guidelines for the prevention of venous thromboembolism were published by the American College of Chest Physicians in September 2004. This set of updated guidelines represents a discussion of treatments of venous thrombosis, thromboprophylaxis, and revision of those published in 2001. These guidelines propose some "official" recommendations for health-care providers for women during the peripartum period. The purpose of this article is to settle some ambiguity and to present these recommendations in a clinical format.
Asunto(s)
Parto , Guías de Práctica Clínica como Asunto , Complicaciones Hematológicas del Embarazo/terapia , Atención Prenatal , Trombofilia/terapia , Adolescente , Adulto , Femenino , Humanos , Embarazo , Sociedades Médicas , Estados Unidos , Trombosis de la Vena/complicaciones , Trombosis de la Vena/etiología , Trombosis de la Vena/genética , Trombosis de la Vena/terapiaRESUMEN
In young women treated for intermediate-high-grade non-Hodgkin's lymphoma with CHOP (cyclophosphamide, adriamycin, oncovine and prednisone), there is insufficient data concerning gonadotoxicity or the need for fertility-preserving measures. The aim of the present study was to evaluate the fertility status in the first complete remission of women who were treated for aggressive non-Hodgkin's lymphoma. A cohort of 36 women with aggressive non-Hodgkin's lymphoma in first remission, who were treated in five university-affiliated hospitals in Israel, was evaluated. All women were aged younger than 40 years at diagnosis and received frontline protocols, including cyclophosphamide and adriamycin, mostly CHOP. Menstrual cycle characteristics, as well as pregnancies before the diagnosis, during treatment and in first complete remission, were evaluated. The patients' mean age at the diagnosis was 28 +/- 7 years (range 17 - 40 years). All patients were treated with chemotherapy, although 10 patients received additional radiotherapy. Follow-up time at first complete remission was 84 +/- 48 months. Before diagnosis, all patients had menstrual cycles, which were regular in 31 (86%). Three patients received gonadtropin-releasing hormone analogs, whereas nine received contraceptive pills together with cytotoxic treatment. During treatment, 18 patients (50%) had amenorrhea, six (17%) had irregular menstrual cycles, and 12 (33%) continued their regular cycles. All but two women resumed menses in the first complete remission, and these were regular in 22 (61%) patients. In 63% of patients, the menstrual cycle recovered within 3 months of the discontinuation of chemotherapy. Eighteen patients (50%) became pregnant during the first complete remission. There was no significant difference between those patients who received fertility-preserving measures versus the remainder concerning regular menstrual cycles recovery or pregnancies. The two patients who developed amenorrhea were 40 years old at the time of diagnosis. In conclusion, the rate of gonadal dysfunction is very low among young, CHOP treated, non-Hodgkin's lymphoma female patients. Fertility-preserving techniques are not needed for women aged younger than 40 years and should probably be reserved for those who are at high risk for gonadal toxicity.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Fertilidad , Infertilidad Femenina/etiología , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/patología , Ciclo Menstrual/efectos de los fármacos , Adolescente , Adulto , Amenorrea , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Estudios de Cohortes , Ciclofosfamida/efectos adversos , Ciclofosfamida/uso terapéutico , Doxorrubicina/efectos adversos , Doxorrubicina/uso terapéutico , Femenino , Humanos , Cinética , Prednisona/efectos adversos , Prednisona/uso terapéutico , Inducción de Remisión , Riesgo , Factores de Tiempo , Vincristina/efectos adversos , Vincristina/uso terapéuticoRESUMEN
OBJECTIVES: Patients with malignancies have an increased prevalence of antiphospholipid antibodies (APA). The aim of this study was to determine the prevalence of IgG, IgM, and IgA anticardiolipin antibodies (aCL) and anti-beta-2 glycoprotein I antibodies (anti-beta2-GPI) in patients with non-Hodgkin's lymphoma (NHL), and to investigate their clinical and prognostic significance. METHODS: The study group included 86 patients with NHL. Enzyme-linked immunosorbent assay kits were used to measure the concentrations of aCL and anti-beta2-GPI, and coagulation tests, to measure lupus anticoagulant (LAC) activity. Blood was collected at diagnosis in all patients and at follow-up in 15. Median follow-up time was 1.9 yr. RESULTS: Elevated APA levels were found in 35 patients (41%) at diagnosis: one patient aCL IgG, five patients aCL IgM, five aCL IgA, one anti-beta2-GPI IgG, 14 anti-beta2-GPI IgM, and 19 anti-beta2-GPI IgA; LAC activity was found in three of 67 patients (4.5%). There was no significant correlation between elevated APA levels and patient's age or sex, disease stage or grade, bone marrow involvement, B symptoms, serum lactate dehydrogenase levels, serum beta2 microglobulin levels, International Prognostic Index (IPI) score, performance status, type of treatment, or response to treatment. There was a correlation between elevated APA and absence of extranodal disease (P = 0.045). A strong negative correlation was found between elevated APA at diagnosis and survival time. Two-year survival was 90 +/- 5% for patients without APA at diagnosis compared with 63 +/- 11% for patients with an elevated APA levels (P = 0.0025). APA added to the predictive value of IPI for event-free and overall survival. CONCLUSIONS: APA are elevated in 41% of NHL patients at diagnosis and are correlated with shortened survival. Their level may serve as an independent prognostic variable in aggressive NHL.
Asunto(s)
Anticuerpos Antifosfolípidos/sangre , Autoanticuerpos/sangre , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Anticardiolipina/sangre , Ensayo de Inmunoadsorción Enzimática , Femenino , Estudios de Seguimiento , Glicoproteínas/inmunología , Humanos , Inhibidor de Coagulación del Lupus/sangre , Linfoma no Hodgkin/terapia , Masculino , Persona de Mediana Edad , Tiempo de Tromboplastina Parcial , Pronóstico , Estudios Retrospectivos , Sensibilidad y Especificidad , Tasa de Supervivencia , Resultado del Tratamiento , beta 2 Glicoproteína IRESUMEN
Alopecia and bone marrow suppression are prominent effects of doxorubicin-containing chemotherapy. The aim of the study was to validate our preliminary clinical observation that the lack of alopecia in Hodgkin lymphoma patients may predict poor response to chemotherapy and low rate of bone marrow suppression. Sixty-six patients with Hodgkin lymphoma were reviewed. They were treated between 1991 and 2001 with at least 4 courses of doxorubicin-containing chemotherapy (MOPP/ABV or ABVD) in 2 university-affiliated hematology departments. Thirty-four patients exhibited complete or near complete alopecia, and 32 retained their hair or had only minimal hair loss. The 2 groups were compared by response to treatment and episodes of bone marrow suppression. Alopecia was associated with a high rate of remission (OR 8.48, 95% CI 2.77-25.95), episodes of neutropenia (OR 3.55, 95% CI 1.28-9.84), leukopenia (OR 1.83, 95% CI 0.68-4.92), delays in scheduled treatments (OR 1.61, 95% CI 0.607-4.30), or number of courses with dose reduction (OR 1.63, 95% CI 0.56-4.74). Significantly more patients with alopecia had at least 1 of these parameters (88% versus 62%, P=0.015; OR 4.50, 95% CI 1.27-15.94). In conclusion, in patients with Hodgkin lymphoma treated with doxorubicin-containing chemotherapy, the absence of alopecia may predict poor response to treatment along with fewer episodes of bone marrow suppression. The absence of alopecia in such patients should alert clinicians to the possibility of treatment failure.